HistoryThis section has been translated automatically.
DefinitionThis section has been translated automatically.
Rare, idiopathic, acquired, acutely onset, sclerosing disease of the skin, subcutaneous fatty tissue and musculature (more rarely is involvement of internal organs) which occurs almost exclusively in patients with advanced chronic renal insufficiency (GFR<30ml/min/1.73m2) after administration of gadolinium-containing contrast media (gadodiamide, gadopentetate dimeglumin).
You might also be interested in
Occurrence/EpidemiologyThis section has been translated automatically.
Rare; currently about 200 cases have been reported in world literature, although a significantly higher incidence can be assumed. The incidence is clearly increasing. No gender preference (in contrast to systemic scleroderma).
EtiopathogenesisThis section has been translated automatically.
ManifestationThis section has been translated automatically.
LocalizationThis section has been translated automatically.
Clinical featuresThis section has been translated automatically.
- Integument: Plaque-shaped and/or diffuse, board-hard (wooden) thickening and hardening of the skin, subcutis and underlying muscles with brownish, yellowish discoloration. Occasionally also papules and subcutaneous nodules. Beginning of the skin changes on the extremities, then spreading to the trunk. Face usually left out. Often in the course of bending contractures with wheelchair use. Burning pain, itching.
- Extracutaneous manifestations: weakness, muscle pain. In individual cases extensive fibrosis and calcification of the diaphragm, the psoas muscle and the kidneys have been observed.
HistologyThis section has been translated automatically.
Differential diagnosisThis section has been translated automatically.
|Scleromyxoedema||nephrogenic systemic fibrosis|
|Face mostly affected||Face free|
|Paraproteins in serum||no paraproteins in serum|
|Plasma cells in the infiltrates||No plasma cells|
|Mucin multiplied||no mucin|
|Fibroblasts reduced||Fibroblasts increased|
TherapyThis section has been translated automatically.
Radiation therapyThis section has been translated automatically.
Progression/forecastThis section has been translated automatically.
Note(s)This section has been translated automatically.
LiteratureThis section has been translated automatically.
- Baron PW et al (2003) Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. At J Dermatopathol 25: 204-209
- Cowper SE, Bucala R (2003) Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. At J Dermatopathy 25: 358
- Galan A et al (2006) Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 18: 614-617
- Haemel AK et al (2011) Update on nephrogenic systemic fibrosis: are we making progress? Int J Dermatol 50:659-666
- High WA (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56: 21-26
- Kobus S et al (2010) Nephrogenic systemic fibrosis-10 cases at the Bochum clinic. JDDG 11: 935
- LeBoit PE (2003) What nephrogenic fibrosing dermopathy might be. Arch Dermatol 139: 928-930
- Mackay-Wiggan JM et al (2003) Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 48: 55-60
- Richmond H et al (2007) Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol 143: 1025-1030
- Ting WW et al (2003) Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 139: 903-906
- Swartz RD et al (2003) Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. On J Med 114: 563-572
Incoming links (9)Contrast medium intolerance; Fibrosis nephrogenic systemic; Gadolinium; Induration; Melphalan; Nephrogenic fibrosing dermopathy; Nephrogenic systemic fibrosis; Pseudoscleroderma; Scleromyxoedema;
Outgoing links (11)Acitretin; Circumscripts of scleroderma (overview); Eosinophilic myalgie syndrome; Fasciitis eosinophil; Gadolinium; Melphalan; Photopheresis extracorporeal; Plasmapheresis; Scleroderma systemic; Scleromyxoedema; ... Show all
Please ask your physician for a reliable diagnosis. This website is only meant as a reference.